TerminatedPhase 1NCT00428272
HGS-ETR2 to Treat Children With Solid Tumors
Studying Embryonal rhabdomyosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Crystal L Mackall, M.D., MDNational Cancer Institute (NCI)
- Intervention
- Lexatumumab alone(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 1-30 years · All sexes
- Timeline
- 2006 – 2015
Study locations (1)
- National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00428272 on ClinicalTrials.govOther trials for Embryonal rhabdomyosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06541262Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid TumorsMilton S. Hershey Medical Center
- RECRUITINGPHASE1NCT04337177Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid TumorsValent Technologies, LLC